Byk Gulden Lomberg Chemische Fabrik Gmbh

Nycomed Gmbh

Takeda Gmbh

Altana Pharma Ag

Dieter Flockerzi

Hans-Peter Kley

Armin Hatzelmann

Hermann Tenor

Beate Schmidt

Degenhard Marx

Christof Zitt

Steffen Weinbrenner

Raimund Külzer

Ulrich Kautz

Wolf-Rudiger Ulrich

Kurt Klemm

Jens Christoffers

Geert Jan Sterk

Felix Reutter

Thomas Maier

Raimund Kuelzer

Martin Viertelhaus

Clemens Braun

Rolf-Peter Hummel

Andrea Wohlsen

Anke Heuser

Anna Rosiak

Christian Hesslinger

Stefan Fischer

Torsten Dunkern

Ewald Benediktus

Imre Schlemminger

Thomas Stengel

Anna Christoffers

Manuela Hessmann

Harald Ohmer

Alexander Mann

Josef Stadlwieser

Hans Christof Holst

Tobias Kanacher

Johannes Barsig

Raimund c/o Nycomed Gmbh Külzer

Jens Prof Dr Christoffers

Maria Vittoria Chiesa

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-thia-10-aza-phenanthrene derivatives

The compounds of formula I in which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors.

Benzonaphthyridines

The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.

Triazolophthalazines

The compounds of formula I in which R1 and R2 have the meanings as given in the description are novel effective PDE2 inhibitors.

The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-oxa-10-aza-phenanthrenes

Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective PDE 3/4 inhibitors.

N-(alkoxyalkyl) carbamoyl-substituted 6-phenyl-benzonaphthyridine derivatives and their use as PDE &#xbe; inhibitors

Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in the description, are novel effective PDE3/4 Inhibitors.

6-phenylbenzonaphthyridines

Benzonaphthyridine-N-oxides comprising a PDE3 and PDE4 inhibiting activity

Compounds 8,9-diethoxy-2-methyl-6-&lsqb;4(p-toluenesulfonamide) phenyl&rsqb;-1,2,3,4,4a,10b-hexahydrobenzo&lsqb;c&rsqb;&lsqb;1,6&rsqb;naphthyridine and 9-ethoxy-8-methoxy-2-methyl-6-&lsqb;4-(p-toluenesulfonamido)phenyl&rsqb;-1,2,3,4,4a,10b-hexahydrobenzo&lsqb;c&rsqb;&lsqb;1,6&rsqb;naphthyridine and medicament compositions based thereon are useful for treating airway disorders, high blood pressure disorders and concomitant disorders connected therewith.

Benzonaphthyridine

Growing community of inventors

Allensbach, Germany

Dieter Flockerzi